Healthcare workers potentially exposed to HIV: an update

Kaveh Asanati¹, Azeem Majeed¹, Lara Shemtob¹ and Fiona Cresswell²,³

¹Department of Primary Care & Public Health, School of Public Health, Imperial College London, London W6 8RP, UK
²Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, BN1 9PX, UK
³MRC-UVRI-London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe, PO Box 49, Uganda

Corresponding author: Kaveh Asanati. Email: K.Asanati@imperial.ac.uk

The risk of contracting HIV from an occupational exposure is very low. There have been no reported cases of occupational HIV transmission in the UK since 1999.¹ From an HIV-positive index case who is not on effective antiretroviral therapy (ART), the risk of HIV acquisition is around 0.3%² (1 in 333) from sharps injuries (e.g. needlestick) and is 0.1%³ (1 in 1000 exposures) from splash injuries (e.g. blood splash to eye). Recent published guidelines provide updated information on the use of post-exposure prophylaxis (PEP) following sexual or occupational exposure to HIV.⁴

The number of people living with undiagnosed HIV infection in the UK is at an all-time low. Of all the people living with HIV in the UK (including undiagnosed individuals), over 85% are on effective ART and are virologically suppressed.⁴ There are now compelling data from numerous studies and geographical settings confirming that HIV virological suppression prevents transmission of HIV following sexual exposures (U = U: undetectable equals untransmittable).⁵–⁸ While there is no evidence about individual level efficacy of ART to prevent transmission following occupational exposures, the same principle is likely to hold true.

With the U = U principle in mind, where the index case has unknown HIV status, the British Association for Sexual Health and HIV (BASHH) recommends the following risk assessment equation to calculate the risk of HIV transmission following a potential exposure⁴:

\[
\text{Risk of HIV transmission} = \text{risk that index case is HIV-positive and with a detectable HIV viral load} \times \text{risk per exposure} \times \frac{1}{333} \text{ for needle stick injury} \times \frac{1}{1000} \text{ for splash injury}
\]

Data from Public Health England suggest the risk that the index case is HIV-positive with a detectable viral load varies widely in the UK with the highest reported risk in gay and bisexual men in London (32 per 1000) and the lowest risk in non-Black African heterosexual women and men (0.1 and 0.2 per 1000, respectively).⁴ People who inject drugs have an overall risk of being HIV-positive with HIV detectable viraemia of 6.7 per 1000.⁴

In light of these data and using the risk assessment equation, the risk of seroconversion following a potential occupational HIV exposure varies from ~1/10,500 (0.01%) following a percutaneous injury from a gay or bisexual man in London to ~1/10,000,000 (0.00001%) following a splash injury from a non-Black African heterosexual woman. Overall, the risk of HIV transmission is very small where the index case has unknown HIV serostatus. For example, the risk of seroconversion from a needlestick injury from a heterosexual British male of unknown status is about 1 in 1,700,000. The risk from a heterosexual British female of unknown HIV status is even less (about 1 in 3,300,000). Therefore, the usual first response measures to a percutaneous injury, including washing the area thoroughly, would suffice as a preventive measure in these cases.

Despite the very low risk of seroconversion, the stress and emotional impact of an occupational exposure to HIV is high.⁹–¹² Therefore, counselling on the actual risk of the exposure usually helps addressing stress and anxiety caused by the incident.

**HIV PEP**

BASHH recommends PEP following a high-risk injury (sharps or mucosal splash) if the index case...
is known to be HIV-positive and has not been on ART for more than six months with a confirmed suppressed HIV viral load (<200 copies/mL) within the last six months.\(^4\) Otherwise, PEP is not generally recommended following other potential occupational HIV exposures unless there is a specific factor that significantly increases the likelihood of transmission (e.g. blood bolus injected or a sharps injury from an injecting drug user in the context of a local HIV outbreak in injecting drug users). Individual risk must be assessed on a case-by-case basis and where there is doubt, an expert opinion should be sought.

The recommended first-line PEP regimen by BASHH is tenofovir disoproxil fumarate 245 mg/emtricitabine 200 mg and raltegravir 1200 mg once daily.\(^4\) Pregnancy and breastfeeding are not contraindications to PEP but women should be counselled appropriately. Raltegravir 400 mg twice daily is preferred as the third agent in pregnancy. In case of treatment failure in the index case, expert advice should be sought.\(^4\) Where indicated, PEP should be started as soon as possible after exposure, preferably within 24 h, but can be considered up to 72 h.\(^4\) Drug interactions must be discussed – raltegravir binds to divalent cations such as iron, aluminium, magnesium and calcium and forms a complex at the level of the gut, which results in less raltegravir being absorbed. Therefore, concomitant use of antacids, iron supplements and multivitamins should ideally be avoided while on once-daily raltegravir. Other concomitant medication interactions can be checked via the Liverpool drug interaction checker.

HIV screening of the exposed individual should be performed at baseline, with a follow-up HIV test at 10.5–12 weeks from the time of exposure with a fourth generation laboratory assay.\(^4\) The recommended PEP regimen is generally well tolerated but those receiving PEP should be warned about adverse drug reactions. Very common side effects (≥1/10) include gastrointestinal effects, sleep disturbance and headache, and more common side effects (≥1/100 to <1/10) include insomnia and abdominal pain.\(^13\) Side effects are usually mild and transient, though where not tolerated, a change to the treatment regimen should be considered.

Despite the very low risk of seroconversion, occupational HIV exposures are extremely anxiety-inducing. Careful risk communication can help in addressing anxiety. PEP is seldom indicated for occupational exposures if the index case is of unknown HIV status, as the transmission risk is very low. PEP is indicated to reduce the transmission risk following high-risk incidents – exposures where the index case is known to be HIV-positive with a detectable viral load – and is most effective if initiated promptly.

**Declarations**

**Competing Interests:** The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: We declare the following interests: KA and FC are members of the guideline writing group of "UK Guideline for the use of HIV Post-Exposure Prophylaxis Following Sexual and Occupational Exposures 2021": AM and LS declare no conflict of interest.

**Funding:** The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Azeem Majeed and Lara Shemtob are supported by the NIHR NW London Applied Research Collaboration (ARC) programme. Fiona Cresswell is supported by an NIHR Academic Clinical Lectureship.

**Ethics approval:** Not applicable.

**Guarantor:** KA.

**Contributorship:** KA wrote the article and received critical feedback from FC, LS and AM.

**Acknowledgements:** The views expressed in this article are those of the authors and not necessarily those of the NIHR or Department of Health and Social Care.

**Provenance:** Not commissioned; peer-reviewed by Neil Snowise and Kieran Fernando.

**ORCID iDs:**
- Kaveh Asanati [https://orcid.org/0000-0002-4455-6102](https://orcid.org/0000-0002-4455-6102)
- Azeem Majeed [https://orcid.org/0000-0002-2357-9858](https://orcid.org/0000-0002-2357-9858)
- Lara Shemtob [https://orcid.org/0000-0002-1187-6329](https://orcid.org/0000-0002-1187-6329)

**References**

1. Public Health England. *Eye of the Needle Report. Surveillance of Significant Occupational Exposures to Bloodborne Viruses in Healthcare Workers in the United Kingdom – Update on Seroconversions*, London: Author, 2020.
2. Smedley J, Dick F and Sadhra S. *Oxford Handbook of Occupational Health*. Oxford: OUP, 2013.
3. Ippolito G, Puro V and De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection. *Arch Intern Med* 1993; 153: 1451–1458.
4. Cresswell F, Asanati K, Bhagani S, Boffito M, Delpech V, Ellis J, et al. UK guideline for the use of HIV post-exposure prophylaxis 2021. *HIV Med* 2022; 23: 494–545.
5. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. *N Engl J Med* 2016; 375: 830–839.
6. Rodger A, Bruun T, Cambiano V, Vernazza P, Estrada V, Van Lunzen J, et al. 153LB: HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER Study. In: *21st Conference on retroviruses and opportunistic infections 2014*, March, pp. 3–6.
7. Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, et al. Viral
suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. *Lancet HIV* 2018; 5: e438–e447.

8. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. *Lancet* 2019; 393: 2428–2438.

9. Wicker S, Stirn AV, Rabenau HF, von Gierke L, Wutzler S and Stephan C. Needlestick injuries: causes, preventability and psychological impact. *Infection* 2014; 42: 549–552.

10. Jeong JS, Son HM, Jeong IS, Son JS, Shin K-S, Yoonchang SW, et al. Qualitative content analysis of psychologic discomfort and coping process after needlestick injuries among health care workers. *Am J Infect Contr* 2016; 44: 183–188.

11. Green B and Griffiths E. Psychiatric consequences of needlestick injury. *Occup Med* 2013; 63: 183–188.

12. Wald J. The psychological consequences of occupational blood and body fluid exposure injuries. *Disabil Rehabil* 2009; 31: 1963–1969.

13. Electronic Medicines Compendium. Truvada SPC. See www.medicines.org.uk/emc/product/3890#UNDESIRABLE_EFFECTS (last checked 1 June 2022).